Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-parvin (PARVG) is one of three mammalian parvin proteins, alongside alpha-parvin (PARVA) and beta-parvin (PARVB). The parvins are actin-binding proteins found at cell-matrix adhesion sites, particularly in focal adhesions where they interact with components such as integrin-linked kinase (ILK) and paxillin. Gamma-parvin is encoded by the *PARVG* gene and contains two calponin homology (CH) domains, characteristic of actin-binding proteins but structurally distinct from other members of the α-actinin superfamily. Unlike PARVA and PARVB, which are widely studied for their roles in cancer and cell motility, gamma-parvin is primarily noted for its function in promoting leukocyte adhesion and spreading[1][2][3]. Its specific contributions seem more narrowly linked to immune cell adhesion biology, with no established role as a therapeutic target, biomarker, or disease modifier. The functional protein family is evolutionarily conserved, and gamma-parvin shares less sequence identity with alpha- and beta-parvin, indicating distinct roles within cells[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-parvin (PARVG).